Predictive and Presymptomatic Testing Market Report 2025

This predictive and presymptomatic testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The predictive and presymptomatic testing market size has grown rapidly in recent years. It will grow from $5.24 billion in 2024 to $5.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing incidence of genetic disorders, rising demand for early diagnosis of chronic diseases, rising prevalence of cancer, increasing adoption of personalized medicine, increasing availability of direct-to-consumer genetic tests.

The predictive and presymptomatic testing market size is expected to see rapid growth in the next few years. It will grow to $8.47 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for early disease detection, increasing investments in biotechnology and genomics, rising demand for non-invasive testing methods, growth in the geriatric population, growth in precision medicine initiatives. Major trends in the forecast period include adoption of personalized medicine, adoption of home testing kits, integration of genomics and big data, development of next generation sequencing (NGS) technologies, implementation of predictive testing in drug development.

The growing prevalence of genetic disorders is expected to drive the expansion of the predictive and presymptomatic testing market in the future. Genetic disorders, caused by abnormalities in deoxyribonucleic acid (DNA) such as gene mutations and chromosome changes, include conditions like cystic fibrosis and Down syndrome. Factors contributing to the increasing incidence of these disorders include advanced maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing is essential in reducing the occurrence of genetic disorders by identifying individuals at risk before symptoms appear. This proactive strategy enables early interventions or lifestyle changes that can help prevent or lessen the severity of these conditions. For example, in June 2023, the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, reported a 10% increase in the number of gene therapies in Phase III clinical trials in the third quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Thus, the increasing prevalence of genetic disorders is fueling the growth of the predictive and presymptomatic testing market.

Key companies in the predictive and presymptomatic testing market are prioritizing technological advancements, such as microbiome-driven predictive models, to improve early detection and offer personalized health insights. These predictive models utilize microbiome data to anticipate potential health issues and enhance early diagnosis. For example, in December 2023, Genefitletics, an Indian biotechnology firm, introduced vascomath, a groundbreaking cardiovascular disease (CVD) prediction model. This model leverages gene expression data from the gut and oral microbiome to detect cardiovascular risks early. It integrates with existing predictive models and provides precision nutrition interventions, representing a major innovation in predictive and presymptomatic testing.

In November 2022, Myriad Genetics, a US-based biotechnology company, acquired Gateway Genomics for an undisclosed sum. This acquisition aims to broaden Myriad's genetic testing portfolio and strengthen its position in the consumer genetics market. Gateway Genomics, also a US-based biotechnology firm, specializes in direct-to-consumer genetic testing and reproductive health solutions.

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

North America was the largest region in the predictive and presymptomatic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive and presymptomatic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Predictive and presymptomatic testing are genetic tests aimed at evaluating an individual's likelihood of developing a disease before any symptoms appear, particularly for inherited conditions. These tests help identify individuals at a higher risk for specific genetic disorders, allowing for early intervention and personalized care. The advantages include early diagnosis, customized prevention strategies, and more informed lifestyle decisions.

The primary forms of testing are predictive and presymptomatic. Predictive testing determines whether an individual has a genetic predisposition to develop a specific condition or disease in the future, even if they currently have no symptoms. Applications include cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and more. These tests are used by hospitals and clinics, diagnostic laboratories, research institutes, and other healthcare providers.

The predictive and presymptomatic testing market research report is one of a series of new reports that provides predictive and presymptomatic testing market statistics, including predictive and presymptomatic testing industry global market size, regional shares, competitors with a predictive and presymptomatic testing market share, detailed predictive and presymptomatic testing market segments, market trends and opportunities, and any further data you may need to thrive in the predictive and presymptomatic testing industry. This predictive and presymptomatic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The predictive and presymptomatic testing market consists of revenues earned by entities by providing services such as genetic testing, risk assessment, early disease detection, biomarker testing, and predictive modelling. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive and presymptomatic testing market also includes sales of carrier screening tests, genetic tests, diagnostic tools, prenatal testing kits, and Alzheimer's disease biomarkers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.